DNA topoisomerase I and DNA gyrase as targets for TB therapy

Nagaraja, Valakunja and Godbole, Adwait A and Henderson, Sara R and Maxwell, Anthony (2017) DNA topoisomerase I and DNA gyrase as targets for TB therapy. In: DRUG DISCOVERY TODAY, 22 (3). pp. 510-518.

PDF Dru_Dis_Tod_22-3_510_2017.pdf - Published Version Restricted to Registered users only Download (2MB) | Request a copy

Abstract

Tuberculosis (TB) is the deadliest bacterial disease in the world. New therapeutic agents are urgently needed to replace existing drugs for which resistance is a significant problem. DNA topoisomerases are well-validated targets for antimicrobial and anticancer chemotherapies. Although bacterial topoisomerase I has yet to be exploited as a target for clinical antibiotics, DNA gyrase has been extensively targeted, including the highly clinically successful fluoroquinolones, which have been utilized in TB therapy. Here, we review the exploitation of topoisomerases as antibacterial targets and summarize progress in developing new agents to target DNA topoisomerase I and DNA gyrase from Mycobacterium tuberculosis.

Item Type:	Journal Article
Publication:	DRUG DISCOVERY TODAY
Additional Information:	Copy right for this article belongs to the ELSEVIER SCI LTD, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
Department/Centre:	Division of Biological Sciences > Microbiology & Cell Biology
Date Deposited:	19 May 2017 10:29
Last Modified:	04 Oct 2018 14:47
URI:	http://eprints.iisc.ac.in/id/eprint/56672

Actions (login required)

View Item